Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with:,- intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), - chronic myelomonocytic leukemia (cmmol (10%-29% marrow blasts without myeloproliferative disorder)), - acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - azacitidine 100mg - powder for injection - 100 mg - active: azacitidine 100mg excipient: mannitol - azacitidine is indicated for the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukaemia (cmmol [10-29 percent marrow blasts without myeloproliferative disorder]), and acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.

Canada - English - Health Canada

dr reddy's laboratories ltd - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - eug-azacitidine is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

Canada - English - Health Canada

fresenius kabi canada ltd - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents

Canada - English - Health Canada

hikma canada limited - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - azacitidine 100mg (105 mg per vial including 5% manufacturing overage) - powder for injection - 100 mg - active: azacitidine 100mg (105 mg per vial including 5% manufacturing overage) excipient: mannitol - indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss). - chronic myelomonocytic leukaemia (cmmol [10%-29% marrow blasts without myeloproliferative disorder]). - acute myeloid leukaemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification, in whom allogenic stem cell transplantation is not indicated.

Canada - English - Health Canada

sandoz canada incorporated - azacitidine - powder for suspension - 100mg - azacitidine 100mg

Canada - English - Health Canada

sterimax inc - azacitidine - powder for suspension - 100mg - azacitidine 100mg

Canada - English - Health Canada

sterimax inc - azacitidine - powder for suspension - 150mg - azacitidine 150mg